Veronika Golovina
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Veronika Golovina has a total of 7 co-authors. Here are the top co-authors by number of shared publications:
- Darina Erechkanova
Pirogov City Clinical Hospital No. 1, 119049 Moscow, Russia
2 shared publications - Evgeny I. Seliverstov
Institute of Surgery of the Pirogov Russian National Research Medical University
2 shared publications I.A. Zolotukhin
2 shared publications- Igor Anatolievich Zolotukhin
Pirogov Russian National Research Medical University
2 shared publications O.I. Efremova
2 shared publications- Vladislav Panfilov
Department of Fundamental and Applied Research in Vascular Surgery, Pirogov Russian National Research Medical University, 119049 Moscow, Russia
2 shared publications
Latest Publications
- Open Access
- 18 December 2024
- Published byΒ MDPI AGΒ inΒ Journal of Clinical Medicine
- Vol.Β 13 Β (24) , 7747
Availability of the Great Saphenous Veins as Conduits for Arterial Bypass Surgery in Patients with Varicose Veins
Background: The great saphenous vein (GSV) has long been recognized as the best conduit for vascular bypass procedures. Concomitant varicose veins disease may be a reason for GSV unavailability either due to dilatation and tortuosity of the vein or due to its destruction during invasive venous treatment. Objectivesβto assess the rate of varicose vein patients with concomitant lower extremity arterial disease (LEAD) who have previously lost their GSV due to venous ablation. Material and Methods: A total of 285 patients (76 F, 209 M) with LEAD were consecutively enrolled. A total of 111 patients (222 limbs) underwent a detailed duplex ultrasound of the lower extremity veins for assessing suitability of the GSV as a conduit. We registered presence of varicose veins (VVs), type of previous invasive procedure and availability of saphenous veins as possible grafts. Results: The mean age of screened patients was 70.5 Β± 9.1.62 (21.75%) patients had varicose veins or were operated on before due to varicose veins. A total of 42 patients with varicose veins had C2 disease, 10 had C3, 9 had C4 and 1 had C6 according to CEAP classification. A total of 222 lower extremities were examined by duplex ultrasound of which 51 limbs had VVs. Despite the presence of varicose tributaries, the GSV was suitable for bypass in 9 of those lower extremities. The GSV was not available as a conduit in 34 (19.9%) ipsilateral lower extremities in the LEAD with no VVs group and in 42 (82.6%) ipsilateral lower extremities in the LEAD with VVs group (p = 0.0001). Varicose vein disease was associated with a higher frequency of the GSV unavailability (odds ratio 18.8, 95% confidence interval 8.35β42.35). On the 11 ipsilateral limbs (5% of LEAD patients and 21.6% of LEAD with VVs patients), the GSV was unavailable due to previous venous interventions. Conclusions: Almost 20% of patients may have both LEAD and VVs. Among those with VVs, most have the ipsilateral GSV unavailable as a potential conduit. Additionally, one fifth of limbs with VVs had GSVs destroyed previously due to saphenous ablative procedures.
- 18 December 2024
- Published byΒ MDPI AGΒ inΒ Journal of Clinical Medicine
- Vol.Β 13 Β (24) , 7747
Open AccessAvailability of the Great Saphenous Veins as Conduits for Arterial Bypass Surgery in Patients with Varicose Veins
Background: The great saphenous vein (GSV) has long been recognized as the best conduit for vascular bypass procedures. Concomitant varicose veins disease may be a reason for GSV unavailability either due to dilatation and tortuosity of the vein or due to its destruction during invasive venous treatment. Objectivesβto assess the rate of varicose vein patients with concomitant lower extremity arterial disease (LEAD) who have previously lost their GSV due to venous ablation. Material and Methods: A total of 285 patients (76 F, 209 M) with LEAD were consecutively enrolled. A total of 111 patients (222 limbs) underwent a detailed duplex ultrasound of the lower extremity veins for assessing suitability of the GSV as a conduit. We registered presence of varicose veins (VVs), type of previous invasive procedure and availability of saphenous veins as possible grafts. Results: The mean age of screened patients was 70.5 Β± 9.1.62 (21.75%) patients had varicose veins or were operated on before due to varicose veins. A total of 42 patients with varicose veins had C2 disease, 10 had C3, 9 had C4 and 1 had C6 according to CEAP classification. A total of 222 lower extremities were examined by duplex ultrasound of which 51 limbs had VVs. Despite the presence of varicose tributaries, the GSV was suitable for bypass in 9 of those lower extremities. The GSV was not available as a conduit in 34 (19.9%) ipsilateral lower extremities in the LEAD with no VVs group and in 42 (82.6%) ipsilateral lower extremities in the LEAD with VVs group (p = 0.0001). Varicose vein disease was associated with a higher frequency of the GSV unavailability (odds ratio 18.8, 95% confidence interval 8.35β42.35). On the 11 ipsilateral limbs (5% of LEAD patients and 21.6% of LEAD with VVs patients), the GSV was unavailable due to previous venous interventions. Conclusions: Almost 20% of patients may have both LEAD and VVs. Among those with VVs, most have the ipsilateral GSV unavailable as a potential conduit. Additionally, one fifth of limbs with VVs had GSVs destroyed previously due to saphenous ablative procedures.
- Open Access
- 6 November 2024
- Published byΒ MDPI AGΒ inΒ Preprints.org
Availability of the Great Saphenous Veins as Conduits for Arterial Bypass Surgery in Patients with Varicose Veins
Background The great saphenous vein (GSV) has long been recognized as a best conduit for vascular bypass procedures. Concomitant varicose veins disease may be a reason for GSV unavailability either due to dilatation and tortuosity of the vein or due to its destruction during invasive venous treatment. Aim - to assess the rate of varicose vein patients with concomitant lower extremity arterial disease (LEAD) who have previously lost their GSV due to venous ablation. Material and methods 285 patients (76 F, 209 M) with LEAD were consecutively enrolled. Demographic data and medical history were taken. Physical examination and duplex ultrasound were performed. We registered presence of varicose veins (VVs), type of previous invasive procedure and availability of saphenous veins as possible grafts. Results Mean age of screened LEAD patients was 70.5Β±9.1. 62 (21.75%) patients had varicose veins or were operated on before due to varicose veins. 42 patients with varicose veins had C2 disease, 10 had C3, nine had C4 and one had C6 according to CEAP classification. Duplex ultrasound examination of the veins of the lower extremities was performed on 111 patients (222 lower extremities). The total number of lower extremities without ipsilateral GSV was 76 (34.2%) due to varicosity, small size, previous ablation or postthrombotic intraluminal changes. 53 limbs in 32 patients had VVs. Despite the presence of varicose tributaries, the GSV was suitable for bypass in 9 lower extremities. GSV was not available as a conduit in 34 (20.1%) ipsilateral lower extremities in the LEAD group and in 42 (79.3%) ipsilateral lower extremities in the LEAD with VVs group (p= 0.0001). Varicose vein disease was associated with a higher frequency of the GSV unavailability odds ratio 18.8 (95% confidence interval 8.35 β 42.35). On the 11 ipsilateral limbs (5%) GSV was unavailable due to previous venous interventions. Conclusions Almost 20% of patients may have both LEAD and VVs. Among those with VVs, most have the ipsilateral GSV unavailable as a potential conduit. Additionally, one fifth of limbs with VVs had GSVs destroyed previously due to saphenous ablative procedures.
- 6 November 2024
- Published byΒ MDPI AGΒ inΒ Preprints.org
Open AccessAvailability of the Great Saphenous Veins as Conduits for Arterial Bypass Surgery in Patients with Varicose Veins
Background The great saphenous vein (GSV) has long been recognized as a best conduit for vascular bypass procedures. Concomitant varicose veins disease may be a reason for GSV unavailability either due to dilatation and tortuosity of the vein or due to its destruction during invasive venous treatment. Aim - to assess the rate of varicose vein patients with concomitant lower extremity arterial disease (LEAD) who have previously lost their GSV due to venous ablation. Material and methods 285 patients (76 F, 209 M) with LEAD were consecutively enrolled. Demographic data and medical history were taken. Physical examination and duplex ultrasound were performed. We registered presence of varicose veins (VVs), type of previous invasive procedure and availability of saphenous veins as possible grafts. Results Mean age of screened LEAD patients was 70.5Β±9.1. 62 (21.75%) patients had varicose veins or were operated on before due to varicose veins. 42 patients with varicose veins had C2 disease, 10 had C3, nine had C4 and one had C6 according to CEAP classification. Duplex ultrasound examination of the veins of the lower extremities was performed on 111 patients (222 lower extremities). The total number of lower extremities without ipsilateral GSV was 76 (34.2%) due to varicosity, small size, previous ablation or postthrombotic intraluminal changes. 53 limbs in 32 patients had VVs. Despite the presence of varicose tributaries, the GSV was suitable for bypass in 9 lower extremities. GSV was not available as a conduit in 34 (20.1%) ipsilateral lower extremities in the LEAD group and in 42 (79.3%) ipsilateral lower extremities in the LEAD with VVs group (p= 0.0001). Varicose vein disease was associated with a higher frequency of the GSV unavailability odds ratio 18.8 (95% confidence interval 8.35 β 42.35). On the 11 ipsilateral limbs (5%) GSV was unavailable due to previous venous interventions. Conclusions Almost 20% of patients may have both LEAD and VVs. Among those with VVs, most have the ipsilateral GSV unavailable as a potential conduit. Additionally, one fifth of limbs with VVs had GSVs destroyed previously due to saphenous ablative procedures.
- 1 January 2021
- Published byΒ Media Sphere Publishing GroupΒ inΒ Journal of Venous Disorders
- Vol.Β 15 Β (2)
Treatment and Secondary Prevention of Venous Thromboembolic Events in Fragile Patients in a Real-life Practice
ΠΡΠ΅Π΄ΡΡΠ°Π²Π»Π΅Π½ ΠΎΠ±Π·ΠΎΡ Π»ΠΈΡΠ΅ΡΠ°ΡΡΡΡ, ΠΏΠΎΡΠ²ΡΡΠ΅Π½Π½ΡΠΉ ΠΏΡΠΎΠ±Π»Π΅ΠΌΠ°ΠΌ ΠΈΡΠΏΠΎΠ»ΡΠ·ΠΎΠ²Π°Π½ΠΈΡ ΠΏΡΡΠΌΡΡ ΠΎΡΠ°Π»ΡΠ½ΡΡ Π°Π½ΡΠΈΠΊΠΎΠ°Π³ΡΠ»ΡΠ½ΡΠΎΠ² (ΠΠΠΠ) ΠΏΡΠΈ Π»Π΅ΡΠ΅Π½ΠΈΠΈ Π²Π΅Π½ΠΎΠ·Π½ΡΡ ΡΡΠΎΠΌΠ±ΠΎΡΠΌΠ±ΠΎΠ»ΠΈΡΠ΅ΡΠΊΠΈΡ ΠΎΡΠ»ΠΎΠΆΠ½Π΅Π½ΠΈΠΉ (ΠΠ’ΠΠ) Ρ Β«Ρ ΡΡΠΏΠΊΠΈΡ Β» ΠΏΠ°ΡΠΈΠ΅Π½ΡΠΎΠ², ΠΊ ΠΊΠΎΡΠΎΡΡΠΌ ΠΎΡΠ½ΠΎΡΡΡΡΡ Π»ΠΈΡΠ° ΡΡΠ°ΡΡΠ΅ΡΠΊΠΎΠ³ΠΎ Π²ΠΎΠ·ΡΠ°ΡΡΠ° (β₯75 Π»Π΅Ρ) ΠΈ/ΠΈΠ»ΠΈ Ρ Π½ΠΈΠ·ΠΊΠΎΠΉ ΠΌΠ°ΡΡΠΎΠΉ ΡΠ΅Π»Π° (β€50 ΠΊΠ³), ΠΈ/ΠΈΠ»ΠΈ Ρ Π½Π°ΡΡΡΠ΅Π½Π½ΠΎΠΉ ΡΡΠ½ΠΊΡΠΈΠ΅ΠΉ ΠΏΠΎΡΠ΅ΠΊ (Π‘ΠΠ€ β€50 ΠΌΠ»/ΠΌΠΈΠ½). ΠΠ½Π°Π»ΠΈΠ·ΠΈΡΡΠ΅ΡΡΡ ΡΡΠ΄ ΠΈΡΡΠ»Π΅Π΄ΠΎΠ²Π°Π½ΠΈΠΉ, ΠΎΡΠ½ΠΎΠ²Π°Π½Π½ΡΡ Π½Π° Π΄Π°Π½Π½ΡΡ ΠΈΠ· ΡΠ΅Π³ΠΈΡΡΡΠΎΠ² RIETE, XALIA, PREFER-VTE ΠΈ ΠΡΠ΅Π·Π΄Π΅Π½ΡΠΊΠΎΠ³ΠΎ ΡΠ΅Π³ΠΈΡΡΡΠ°, Π° ΡΠ°ΠΊΠΆΠ΅ Π΄ΡΡΠ³ΠΈΡ ΠΈΡΡΠ»Π΅Π΄ΠΎΠ²Π°Π½ΠΈΠΉ, ΡΠ°ΡΡΠΌΠ°ΡΡΠΈΠ²Π°ΡΡΠΈΡ Π°Π½ΡΠΈΠΊΠΎΠ°Π³ΡΠ»ΡΠ½ΡΠ½ΡΡ ΡΠ΅ΡΠ°ΠΏΠΈΡ Ρ ΡΡΠΎΠΉ ΠΊΠ°ΡΠ΅Π³ΠΎΡΠΈΠΈ ΠΏΠ°ΡΠΈΠ΅Π½ΡΠΎΠ². Π‘Π΄Π΅Π»Π°Π½Ρ Π²ΡΠ²ΠΎΠ΄Ρ, ΡΡΠΎ Π² Π³ΡΡΠΏΠΏΠ΅ Β«Ρ ΡΡΠΏΠΊΠΈΡ Β» ΠΏΠ°ΡΠΈΠ΅Π½ΡΠΎΠ², ΠΏΡΠΈΠ½ΠΈΠΌΠ°ΡΡΠΈΡ Π°Π½ΡΠΈΠΊΠΎΠ°Π³ΡΠ»ΡΠ½ΡΠ½ΡΡ ΡΠ΅ΡΠ°ΠΏΠΈΡ ΠΏΠΎ ΠΏΠΎΠ²ΠΎΠ΄Ρ ΠΠ’ΠΠ, Π·Π½Π°ΡΠΈΡΠ΅Π»ΡΠ½ΠΎ ΠΏΠΎΠ²ΡΡΠ΅Π½ ΡΠΈΡΠΊ Π³Π΅ΠΌΠΎΡΡΠ°Π³ΠΈΡΠ΅ΡΠΊΠΈΡ ΠΎΡΠ»ΠΎΠΆΠ½Π΅Π½ΠΈΠΉ Π² ΡΡΠ°Π²Π½Π΅Π½ΠΈΠΈ Ρ ΡΠΈΡΠΊΠΎΠΌ ΠΏΠΎΠ²ΡΠΎΡΠ½ΠΎΠ³ΠΎ ΠΠ’ΠΠ. ΠΠΎΠΌΠΈΠΌΠΎ ΡΡΠΎΠ³ΠΎ, ΡΡΠ°Π²Π½ΠΈΡΠ΅Π»ΡΠ½ΡΠΉ Π°Π½Π°Π»ΠΈΠ· ΠΠΠΠ ΡΠΎ ΡΡΠ°Π½Π΄Π°ΡΡΠ½ΠΎΠΉ Π°Π½ΡΠΈΠΊΠΎΠ°Π³ΡΠ»ΡΠ½ΡΠ½ΠΎΠΉ ΡΠ΅ΡΠ°ΠΏΠΈΠ΅ΠΉ ΠΏΠΎΠΊΠ°Π·Π°Π» ΡΡΠ΄ ΠΏΡΠ΅ΠΈΠΌΡΡΠ΅ΡΡΠ² Π² Π²ΠΈΠ΄Π΅ ΡΠ½ΠΈΠΆΠ΅Π½ΠΈΡ ΡΠ°ΡΡΠΎΡΡ ΡΠ°Π·Π²ΠΈΡΠΈΡ Π±ΠΎΠ»ΡΡΠΎΠ³ΠΎ ΠΊΡΠΎΠ²ΠΎΡΠ΅ΡΠ΅Π½ΠΈΡ ΠΈ ΡΠΈΡΠΊΠ° ΡΠ΅ΡΠΈΠ΄ΠΈΠ²Π° ΠΠ’ΠΠ. ΠΡΠ΅Π΄ΡΡΠ°Π²Π»Π΅Π½Π½ΡΠ΅ Π΄Π°Π½Π½ΡΠ΅ ΠΌΠΎΠ³ΡΡ Π±ΡΡΡ ΠΈΡΠΏΠΎΠ»ΡΠ·ΠΎΠ²Π°Π½Ρ Π² ΠΊΠ°ΡΠ΅ΡΡΠ²Π΅ ΠΏΠΎΠΌΠΎΡΠΈ ΠΏΡΠΈ Π²ΡΠ±ΠΎΡΠ΅ Π½Π°ΠΈΠ±ΠΎΠ»Π΅Π΅ ΡΠ°ΡΠΈΠΎΠ½Π°Π»ΡΠ½ΠΎΠ³ΠΎ ΠΌΠ΅ΡΠΎΠ΄Π° Π»Π΅ΡΠ΅Π½ΠΈΡ ΠΠ’ΠΠ Ρ Β«Ρ ΡΡΠΏΠΊΠΈΡ Β» ΠΏΠ°ΡΠΈΠ΅Π½ΡΠΎΠ².
- 1 January 2021
- Published byΒ Media Sphere Publishing GroupΒ inΒ Journal of Venous Disorders
- Vol.Β 15 Β (2)
Treatment and Secondary Prevention of Venous Thromboembolic Events in Fragile Patients in a Real-life Practice
ΠΡΠ΅Π΄ΡΡΠ°Π²Π»Π΅Π½ ΠΎΠ±Π·ΠΎΡ Π»ΠΈΡΠ΅ΡΠ°ΡΡΡΡ, ΠΏΠΎΡΠ²ΡΡΠ΅Π½Π½ΡΠΉ ΠΏΡΠΎΠ±Π»Π΅ΠΌΠ°ΠΌ ΠΈΡΠΏΠΎΠ»ΡΠ·ΠΎΠ²Π°Π½ΠΈΡ ΠΏΡΡΠΌΡΡ ΠΎΡΠ°Π»ΡΠ½ΡΡ Π°Π½ΡΠΈΠΊΠΎΠ°Π³ΡΠ»ΡΠ½ΡΠΎΠ² (ΠΠΠΠ) ΠΏΡΠΈ Π»Π΅ΡΠ΅Π½ΠΈΠΈ Π²Π΅Π½ΠΎΠ·Π½ΡΡ ΡΡΠΎΠΌΠ±ΠΎΡΠΌΠ±ΠΎΠ»ΠΈΡΠ΅ΡΠΊΠΈΡ ΠΎΡΠ»ΠΎΠΆΠ½Π΅Π½ΠΈΠΉ (ΠΠ’ΠΠ) Ρ Β«Ρ ΡΡΠΏΠΊΠΈΡ Β» ΠΏΠ°ΡΠΈΠ΅Π½ΡΠΎΠ², ΠΊ ΠΊΠΎΡΠΎΡΡΠΌ ΠΎΡΠ½ΠΎΡΡΡΡΡ Π»ΠΈΡΠ° ΡΡΠ°ΡΡΠ΅ΡΠΊΠΎΠ³ΠΎ Π²ΠΎΠ·ΡΠ°ΡΡΠ° (β₯75 Π»Π΅Ρ) ΠΈ/ΠΈΠ»ΠΈ Ρ Π½ΠΈΠ·ΠΊΠΎΠΉ ΠΌΠ°ΡΡΠΎΠΉ ΡΠ΅Π»Π° (β€50 ΠΊΠ³), ΠΈ/ΠΈΠ»ΠΈ Ρ Π½Π°ΡΡΡΠ΅Π½Π½ΠΎΠΉ ΡΡΠ½ΠΊΡΠΈΠ΅ΠΉ ΠΏΠΎΡΠ΅ΠΊ (Π‘ΠΠ€ β€50 ΠΌΠ»/ΠΌΠΈΠ½). ΠΠ½Π°Π»ΠΈΠ·ΠΈΡΡΠ΅ΡΡΡ ΡΡΠ΄ ΠΈΡΡΠ»Π΅Π΄ΠΎΠ²Π°Π½ΠΈΠΉ, ΠΎΡΠ½ΠΎΠ²Π°Π½Π½ΡΡ Π½Π° Π΄Π°Π½Π½ΡΡ ΠΈΠ· ΡΠ΅Π³ΠΈΡΡΡΠΎΠ² RIETE, XALIA, PREFER-VTE ΠΈ ΠΡΠ΅Π·Π΄Π΅Π½ΡΠΊΠΎΠ³ΠΎ ΡΠ΅Π³ΠΈΡΡΡΠ°, Π° ΡΠ°ΠΊΠΆΠ΅ Π΄ΡΡΠ³ΠΈΡ ΠΈΡΡΠ»Π΅Π΄ΠΎΠ²Π°Π½ΠΈΠΉ, ΡΠ°ΡΡΠΌΠ°ΡΡΠΈΠ²Π°ΡΡΠΈΡ Π°Π½ΡΠΈΠΊΠΎΠ°Π³ΡΠ»ΡΠ½ΡΠ½ΡΡ ΡΠ΅ΡΠ°ΠΏΠΈΡ Ρ ΡΡΠΎΠΉ ΠΊΠ°ΡΠ΅Π³ΠΎΡΠΈΠΈ ΠΏΠ°ΡΠΈΠ΅Π½ΡΠΎΠ². Π‘Π΄Π΅Π»Π°Π½Ρ Π²ΡΠ²ΠΎΠ΄Ρ, ΡΡΠΎ Π² Π³ΡΡΠΏΠΏΠ΅ Β«Ρ ΡΡΠΏΠΊΠΈΡ Β» ΠΏΠ°ΡΠΈΠ΅Π½ΡΠΎΠ², ΠΏΡΠΈΠ½ΠΈΠΌΠ°ΡΡΠΈΡ Π°Π½ΡΠΈΠΊΠΎΠ°Π³ΡΠ»ΡΠ½ΡΠ½ΡΡ ΡΠ΅ΡΠ°ΠΏΠΈΡ ΠΏΠΎ ΠΏΠΎΠ²ΠΎΠ΄Ρ ΠΠ’ΠΠ, Π·Π½Π°ΡΠΈΡΠ΅Π»ΡΠ½ΠΎ ΠΏΠΎΠ²ΡΡΠ΅Π½ ΡΠΈΡΠΊ Π³Π΅ΠΌΠΎΡΡΠ°Π³ΠΈΡΠ΅ΡΠΊΠΈΡ ΠΎΡΠ»ΠΎΠΆΠ½Π΅Π½ΠΈΠΉ Π² ΡΡΠ°Π²Π½Π΅Π½ΠΈΠΈ Ρ ΡΠΈΡΠΊΠΎΠΌ ΠΏΠΎΠ²ΡΠΎΡΠ½ΠΎΠ³ΠΎ ΠΠ’ΠΠ. ΠΠΎΠΌΠΈΠΌΠΎ ΡΡΠΎΠ³ΠΎ, ΡΡΠ°Π²Π½ΠΈΡΠ΅Π»ΡΠ½ΡΠΉ Π°Π½Π°Π»ΠΈΠ· ΠΠΠΠ ΡΠΎ ΡΡΠ°Π½Π΄Π°ΡΡΠ½ΠΎΠΉ Π°Π½ΡΠΈΠΊΠΎΠ°Π³ΡΠ»ΡΠ½ΡΠ½ΠΎΠΉ ΡΠ΅ΡΠ°ΠΏΠΈΠ΅ΠΉ ΠΏΠΎΠΊΠ°Π·Π°Π» ΡΡΠ΄ ΠΏΡΠ΅ΠΈΠΌΡΡΠ΅ΡΡΠ² Π² Π²ΠΈΠ΄Π΅ ΡΠ½ΠΈΠΆΠ΅Π½ΠΈΡ ΡΠ°ΡΡΠΎΡΡ ΡΠ°Π·Π²ΠΈΡΠΈΡ Π±ΠΎΠ»ΡΡΠΎΠ³ΠΎ ΠΊΡΠΎΠ²ΠΎΡΠ΅ΡΠ΅Π½ΠΈΡ ΠΈ ΡΠΈΡΠΊΠ° ΡΠ΅ΡΠΈΠ΄ΠΈΠ²Π° ΠΠ’ΠΠ. ΠΡΠ΅Π΄ΡΡΠ°Π²Π»Π΅Π½Π½ΡΠ΅ Π΄Π°Π½Π½ΡΠ΅ ΠΌΠΎΠ³ΡΡ Π±ΡΡΡ ΠΈΡΠΏΠΎΠ»ΡΠ·ΠΎΠ²Π°Π½Ρ Π² ΠΊΠ°ΡΠ΅ΡΡΠ²Π΅ ΠΏΠΎΠΌΠΎΡΠΈ ΠΏΡΠΈ Π²ΡΠ±ΠΎΡΠ΅ Π½Π°ΠΈΠ±ΠΎΠ»Π΅Π΅ ΡΠ°ΡΠΈΠΎΠ½Π°Π»ΡΠ½ΠΎΠ³ΠΎ ΠΌΠ΅ΡΠΎΠ΄Π° Π»Π΅ΡΠ΅Π½ΠΈΡ ΠΠ’ΠΠ Ρ Β«Ρ ΡΡΠΏΠΊΠΈΡ Β» ΠΏΠ°ΡΠΈΠ΅Π½ΡΠΎΠ².
- 1 January 2021
- Published byΒ Media Sphere Publishing GroupΒ inΒ Journal of Venous Disorders
- Vol.Β 15 Β (2)
Cytokines in Pathogenesis of Varicose Veins
ΠΠ°ΡΠΎΠ³Π΅Π½Π΅Π· Π²Π°ΡΠΈΠΊΠΎΠ·Π½ΠΎΠΉ Π±ΠΎΠ»Π΅Π·Π½ΠΈ Π΄ΠΎ ΡΠΈΡ ΠΏΠΎΡ ΠΎΡΡΠ°Π΅ΡΡΡ Π΄ΠΎ ΠΊΠΎΠ½ΡΠ° Π½Π΅ ΠΈΠ·ΡΡΠ΅Π½Π½ΡΠΌ ΠΈ ΡΠ»ΡΠΆΠΈΡ ΠΏΡΠ΅Π΄ΠΌΠ΅ΡΠΎΠΌ Π°ΠΊΡΠΈΠ²Π½ΠΎΠ³ΠΎ ΠΈΡΡΠ»Π΅Π΄ΠΎΠ²Π°Π½ΠΈΡ ΠΊΠ»ΠΈΠ½ΠΈΡΠΈΡΡΠΎΠ² ΠΈ ΡΡΠ΅Π½ΡΡ ΡΡΠ½Π΄Π°ΠΌΠ΅Π½ΡΠ°Π»ΡΠ½ΡΡ Π½Π°ΠΏΡΠ°Π²Π»Π΅Π½ΠΈΠΉ ΠΌΠ΅Π΄ΠΈΡΠΈΠ½Ρ. ΠΡΠΈΡΠΈΠ½ΠΎΠΉ ΡΠ·Π»ΠΎΠ²Π°ΡΠΎΠΉ ΡΡΠ°Π½ΡΡΠΎΡΠΌΠ°ΡΠΈΠΈ ΠΏΡΠΈΠ·Π½Π°ΡΡ ΡΠ΅ΠΌΠΎΠ΄Π΅Π»ΠΈΡΠΎΠ²Π°Π½ΠΈΠ΅ Π²Π΅Π½ΠΎΠ·Π½ΠΎΠΉ ΡΡΠ΅Π½ΠΊΠΈ, ΠΊΠΎΡΠΎΡΠΎΠ΅, Π² ΡΠ²ΠΎΡ ΠΎΡΠ΅ΡΠ΅Π΄Ρ, ΡΠ°Π·Π²ΠΈΠ²Π°Π΅ΡΡΡ Π² ΡΠ΅Π·ΡΠ»ΡΡΠ°ΡΠ΅ ΡΠ°ΠΊ Π½Π°Π·ΡΠ²Π°Π΅ΠΌΠΎΠ³ΠΎ Π²Π΅Π½ΠΎΡΠΏΠ΅ΡΠΈΡΠΈΡΠ΅ΡΠΊΠΎΠ³ΠΎ Π²ΠΎΡΠΏΠ°Π»Π΅Π½ΠΈΡ. ΠΡΠΎΡ Ρ ΡΠΎΠ½ΠΈΡΠ΅ΡΠΊΠΈΠΉ ΠΏΡΠΎΡΠ΅ΡΡ Π²ΠΊΠ»ΡΡΠ°Π΅Ρ ΠΊΠΎΠΌΠΏΠ»Π΅ΠΊΡ Π²Π·Π°ΠΈΠΌΠΎΠ΄Π΅ΠΉΡΡΠ²ΠΈΠΉ ΠΌΠ΅ΠΆΠ΄Ρ ΠΊΠ»Π΅ΡΠΊΠ°ΠΌΠΈ, ΠΎΡΠ²Π΅ΡΠ°ΡΡΠΈΠΌΠΈ Π·Π° Π²ΠΎΡΠΏΠ°Π»ΠΈΡΠ΅Π»ΡΠ½ΡΡ ΡΠ΅Π°ΠΊΡΠΈΡ (Π½Π΅ΠΉΡΡΠΎΡΠΈΠ»Ρ, Π»ΠΈΠΌΡΠΎΡΠΈΡΡ, ΠΌΠΎΠ½ΠΎΡΠΈΡΡ, ΠΌΠ°ΠΊΡΠΎΡΠ°Π³ΠΈ), ΡΠ½Π΄ΠΎΡΠ΅Π»ΠΈΠ°Π»ΡΠ½ΡΠΌΠΈ ΠΊΠ»Π΅ΡΠΊΠ°ΠΌΠΈ, Π³Π»Π°Π΄ΠΊΠΎΠΌΡΡΠ΅ΡΠ½ΡΠΌΠΈ ΠΊΠ»Π΅ΡΠΊΠ°ΠΌΠΈ ΡΠΎΡΡΠ΄ΠΎΠ² ΠΈ Π²Π½Π΅ΠΊΠ»Π΅ΡΠΎΡΠ½ΡΠΌ ΠΌΠ°ΡΡΠΈΠΊΡΠΎΠΌ. ΠΡΠΎΠΌΠ΅ ΡΠΎΠ³ΠΎ, Π²Π΅Π½ΠΎΡΠΏΠ΅ΡΠΈΡΠΈΡΠ΅ΡΠΊΠΎΠ΅ Π²ΠΎΡΠΏΠ°Π»Π΅Π½ΠΈΠ΅ ΠΏΡΠΎΡΠ΅ΠΊΠ°Π΅Ρ ΠΏΡΠΈ Π°ΠΊΡΠΈΠ²Π½ΠΎΠΌ ΡΡΠ°ΡΡΠΈΠΈ ΡΠΈΡΠΎΠΊΠΈΠ½ΠΎΠ², ΠΊΠΎΡΠΎΡΡΠ΅ ΠΏΡΠ΅Π΄ΡΡΠ°Π²Π»ΡΡΡ ΡΠΎΠ±ΠΎΠΉ ΡΠ°Π·Π½ΠΎΠΎΠ±ΡΠ°Π·Π½ΡΡ Π³ΡΡΠΏΠΏΡ Π½Π΅Π±ΠΎΠ»ΡΡΠΈΡ Π±Π΅Π»ΠΊΠΎΠ², ΠΏΡΠΎΠ΄ΡΡΠΈΡΡΠ΅ΠΌΡΡ ΡΠ°Π·Π½ΡΠΌΠΈ ΠΈΠΌΠΌΡΠ½Π½ΡΠΌΠΈ ΠΈ ΡΠΎΡΡΠ΄ΠΈΡΡΡΠΌΠΈ ΠΊΠ»Π΅ΡΠΊΠ°ΠΌΠΈ, ΠΊΠΎΡΠΎΡΡΠ΅, Π΄Π΅ΠΉΡΡΠ²ΡΡ Π² ΠΏΠΈΠΊΠΎΠΌΠΎΠ»ΡΡΠ½ΡΡ ΠΈ Π½Π°Π½ΠΎΠΌΠΎΠ»ΡΡΠ½ΡΡ ΠΊΠΎΠ½ΡΠ΅Π½ΡΡΠ°ΡΠΈΡΡ , Π°ΠΊΡΠΈΠ²ΠΈΡΡΡΡ ΡΠΏΠ΅ΡΠΈΡΠΈΡΠ΅ΡΠΊΠΈΠ΅ ΡΠ΅ΡΠ΅ΠΏΡΠΎΡΡ ΠΈ ΠΌΠΎΠ΄ΡΠ»ΠΈΡΡΡΡ ΡΡΠ½ΠΊΡΠΈΠΈ ΠΌΠ½ΠΎΠ³ΠΈΡ ΠΊΠ»Π΅ΡΠΎΠΊ ΠΈ ΡΠΊΠ°Π½Π΅ΠΉ. Π ΠΎΠ»Ρ ΡΠΈΡΠΎΠΊΠΈΠ½ΠΎΠ² Π² ΠΏΠ°ΡΠΎΠ³Π΅Π½Π΅Π·Π΅ Π²Π°ΡΠΈΠΊΠΎΠ·Π½ΠΎΠΉ Π±ΠΎΠ»Π΅Π·Π½ΠΈ ΠΎΡΡΠ°Π΅ΡΡΡ ΠΌΠ°Π»ΠΎΠΈΠ·ΡΡΠ΅Π½Π½ΠΎΠΉ Π²Π²ΠΈΠ΄Ρ ΡΠ»ΠΎΠΆΠ½ΠΎΡΡΠΈ ΠΈΠ·ΡΡΠ΅Π½ΠΈΡ ΠΈΡ ΠΌΠ΅Ρ Π°Π½ΠΈΠ·ΠΌΠ° Π΄Π΅ΠΉΡΡΠ²ΠΈΡ. ΠΡΠ΅Π΄ΠΏΠΎΠ»Π°Π³Π°Π΅ΡΡΡ, ΡΡΠΎ ΠΈΡ Π°ΠΊΡΠΈΠ²Π½ΠΎΡΡΡ ΠΎΠΏΠΎΡΡΠ΅Π΄ΡΠ΅Ρ Π½Π°ΡΡΡΠ΅Π½ΠΈΡ ΡΠ΅Π³ΡΠ»ΠΈΡΠΎΠ²Π°Π½ΠΈΡ Π΄Π΅Π³ΡΠ°Π΄Π°ΡΠΈΠΈ Π²Π½Π΅ΠΊΠ»Π΅ΡΠΎΡΠ½ΠΎΠ³ΠΎ ΠΌΠ°ΡΡΠΈΠΊΡΠ°, Π²ΠΈΠ΄ΠΎΠΈΠ·ΠΌΠ΅Π½Π΅Π½ΠΈΠ΅ ΡΠΎΡΡΠ°Π²Π»ΡΡΡΠΈΡ Π²Π½Π΅ΠΊΠ»Π΅ΡΠΎΡΠ½ΠΎΠ³ΠΎ ΠΌΠ°ΡΡΠΈΠΊΡΠ°, ΡΠ°ΠΊΠΈΡ ΠΊΠ°ΠΊ ΠΊΠΎΠ»Π»Π°Π³Π΅Π½ ΠΈ ΡΠ»Π°ΡΡΠΈΠ½, ΡΠ½ΠΈΠΆΠ΅Π½ΠΈΠ΅ ΠΊΠΎΠ»ΠΈΡΠ΅ΡΡΠ²Π° Π³Π»Π°Π΄ΠΊΠΎΠΌΡΡΠ΅ΡΠ½ΡΡ ΠΊΠ»Π΅ΡΠΎΠΊ, ΡΡΠΎ ΠΏΡΠΈΠ²ΠΎΠ΄ΠΈΡ ΠΊ ΡΠ½ΠΈΠΆΠ΅Π½ΠΈΡ ΡΡΡΠ΅ΠΊΡΠΈΠ²Π½ΠΎΡΡΠΈ ΡΠΎΠΊΡΠ°ΡΠ΅Π½ΠΈΡ ΡΠΎΡΡΠ΄ΠΈΡΡΠΎΠΉ ΡΡΠ΅Π½ΠΊΠΈ ΠΈΠ·-Π·Π° ΡΡΠ°Π³ΠΌΠ΅Π½ΡΠ°ΡΠΈΠΈ ΠΌΡΡΠ΅ΡΠ½ΠΎΠ³ΠΎ ΡΠ»ΠΎΡ Π²Π΅Π½Ρ. Π¦ΠΈΡΠΎΠΊΠΈΠ½Ρ ΡΡΠ°ΡΡΠ²ΡΡΡ ΠΈ Π² ΠΏΡΠΎΡΠ΅ΡΡΠ°Ρ Π°ΠΊΡΠΈΠ²Π°ΡΠΈΠΈ Π»Π΅ΠΉΠΊΠΎΡΠΈΡΠΎΠ², ΡΡΠΎ ΠΏΡΠΈΠ²ΠΎΠ΄ΠΈΡ ΠΊ Π²ΡΡΠ²ΠΎΠ±ΠΎΠΆΠ΄Π΅Π½ΠΈΡ ΡΠ²ΠΎΠ±ΠΎΠ΄Π½ΡΡ ΡΠ°Π΄ΠΈΠΊΠ°Π»ΠΎΠ², Π°ΠΊΡΠΈΠ²Π°ΡΠΈΠΈ ΠΏΡΠΎΡΠ΅Π°Π·Ρ ΠΈ ΠΏΠΎΡΠ»Π΅Π΄ΡΡΡΠ΅ΠΉ Π΄Π΅Π³ΡΠ°Π΄Π°ΡΠΈΠΈ Π³Π»Π°Π΄ΠΊΠΎΠΌΡΡΠ΅ΡΠ½ΡΡ ΠΊΠ»Π΅ΡΠΎΠΊ. Π ΡΠ°ΠΌΠΊΠ°Ρ Π΄Π°Π½Π½ΠΎΠΉ ΡΠ°Π±ΠΎΡΡ ΠΏΡΠ΅Π΄ΡΡΠ°Π²Π»Π΅Π½Π° ΠΎΠ±ΡΠ°Ρ ΠΈΠ½ΡΠΎΡΠΌΠ°ΡΠΈΡ ΠΎ ΡΠΈΡΠΎΠΊΠΈΠ½Π°Ρ , Π° ΡΠ°ΠΊΠΆΠ΅ ΠΏΡΠΎΠ²Π΅Π΄Π΅Π½ Π°Π½Π°Π»ΠΈΠ· ΠΈΡΡΠ»Π΅Π΄ΠΎΠ²Π°Π½ΠΈΠΉ, Π² ΠΊΠΎΡΠΎΡΡΡ ΠΈΠ·ΡΡΠ΅Π½ΠΎ Π²ΠΎΠ·ΠΌΠΎΠΆΠ½ΠΎΠ΅ Π²Π»ΠΈΡΠ½ΠΈΠ΅ ΡΠ°Π·Π»ΠΈΡΠ½ΡΡ ΠΌΠΎΠ»Π΅ΠΊΡΠ» Π½Π° ΡΠ°Π·Π²ΠΈΡΠΈΠ΅ ΠΏΠ΅ΡΠ²ΠΈΡΠ½ΠΎΠ³ΠΎ Π²Π°ΡΠΈΠΊΠΎΠ·Π½ΠΎΠ³ΠΎ ΡΠ°ΡΡΠΈΡΠ΅Π½ΠΈΡ Π²Π΅Π½.
- 1 January 2021
- Published byΒ Media Sphere Publishing GroupΒ inΒ Journal of Venous Disorders
- Vol.Β 15 Β (2)
Cytokines in Pathogenesis of Varicose Veins
ΠΠ°ΡΠΎΠ³Π΅Π½Π΅Π· Π²Π°ΡΠΈΠΊΠΎΠ·Π½ΠΎΠΉ Π±ΠΎΠ»Π΅Π·Π½ΠΈ Π΄ΠΎ ΡΠΈΡ ΠΏΠΎΡ ΠΎΡΡΠ°Π΅ΡΡΡ Π΄ΠΎ ΠΊΠΎΠ½ΡΠ° Π½Π΅ ΠΈΠ·ΡΡΠ΅Π½Π½ΡΠΌ ΠΈ ΡΠ»ΡΠΆΠΈΡ ΠΏΡΠ΅Π΄ΠΌΠ΅ΡΠΎΠΌ Π°ΠΊΡΠΈΠ²Π½ΠΎΠ³ΠΎ ΠΈΡΡΠ»Π΅Π΄ΠΎΠ²Π°Π½ΠΈΡ ΠΊΠ»ΠΈΠ½ΠΈΡΠΈΡΡΠΎΠ² ΠΈ ΡΡΠ΅Π½ΡΡ ΡΡΠ½Π΄Π°ΠΌΠ΅Π½ΡΠ°Π»ΡΠ½ΡΡ Π½Π°ΠΏΡΠ°Π²Π»Π΅Π½ΠΈΠΉ ΠΌΠ΅Π΄ΠΈΡΠΈΠ½Ρ. ΠΡΠΈΡΠΈΠ½ΠΎΠΉ ΡΠ·Π»ΠΎΠ²Π°ΡΠΎΠΉ ΡΡΠ°Π½ΡΡΠΎΡΠΌΠ°ΡΠΈΠΈ ΠΏΡΠΈΠ·Π½Π°ΡΡ ΡΠ΅ΠΌΠΎΠ΄Π΅Π»ΠΈΡΠΎΠ²Π°Π½ΠΈΠ΅ Π²Π΅Π½ΠΎΠ·Π½ΠΎΠΉ ΡΡΠ΅Π½ΠΊΠΈ, ΠΊΠΎΡΠΎΡΠΎΠ΅, Π² ΡΠ²ΠΎΡ ΠΎΡΠ΅ΡΠ΅Π΄Ρ, ΡΠ°Π·Π²ΠΈΠ²Π°Π΅ΡΡΡ Π² ΡΠ΅Π·ΡΠ»ΡΡΠ°ΡΠ΅ ΡΠ°ΠΊ Π½Π°Π·ΡΠ²Π°Π΅ΠΌΠΎΠ³ΠΎ Π²Π΅Π½ΠΎΡΠΏΠ΅ΡΠΈΡΠΈΡΠ΅ΡΠΊΠΎΠ³ΠΎ Π²ΠΎΡΠΏΠ°Π»Π΅Π½ΠΈΡ. ΠΡΠΎΡ Ρ ΡΠΎΠ½ΠΈΡΠ΅ΡΠΊΠΈΠΉ ΠΏΡΠΎΡΠ΅ΡΡ Π²ΠΊΠ»ΡΡΠ°Π΅Ρ ΠΊΠΎΠΌΠΏΠ»Π΅ΠΊΡ Π²Π·Π°ΠΈΠΌΠΎΠ΄Π΅ΠΉΡΡΠ²ΠΈΠΉ ΠΌΠ΅ΠΆΠ΄Ρ ΠΊΠ»Π΅ΡΠΊΠ°ΠΌΠΈ, ΠΎΡΠ²Π΅ΡΠ°ΡΡΠΈΠΌΠΈ Π·Π° Π²ΠΎΡΠΏΠ°Π»ΠΈΡΠ΅Π»ΡΠ½ΡΡ ΡΠ΅Π°ΠΊΡΠΈΡ (Π½Π΅ΠΉΡΡΠΎΡΠΈΠ»Ρ, Π»ΠΈΠΌΡΠΎΡΠΈΡΡ, ΠΌΠΎΠ½ΠΎΡΠΈΡΡ, ΠΌΠ°ΠΊΡΠΎΡΠ°Π³ΠΈ), ΡΠ½Π΄ΠΎΡΠ΅Π»ΠΈΠ°Π»ΡΠ½ΡΠΌΠΈ ΠΊΠ»Π΅ΡΠΊΠ°ΠΌΠΈ, Π³Π»Π°Π΄ΠΊΠΎΠΌΡΡΠ΅ΡΠ½ΡΠΌΠΈ ΠΊΠ»Π΅ΡΠΊΠ°ΠΌΠΈ ΡΠΎΡΡΠ΄ΠΎΠ² ΠΈ Π²Π½Π΅ΠΊΠ»Π΅ΡΠΎΡΠ½ΡΠΌ ΠΌΠ°ΡΡΠΈΠΊΡΠΎΠΌ. ΠΡΠΎΠΌΠ΅ ΡΠΎΠ³ΠΎ, Π²Π΅Π½ΠΎΡΠΏΠ΅ΡΠΈΡΠΈΡΠ΅ΡΠΊΠΎΠ΅ Π²ΠΎΡΠΏΠ°Π»Π΅Π½ΠΈΠ΅ ΠΏΡΠΎΡΠ΅ΠΊΠ°Π΅Ρ ΠΏΡΠΈ Π°ΠΊΡΠΈΠ²Π½ΠΎΠΌ ΡΡΠ°ΡΡΠΈΠΈ ΡΠΈΡΠΎΠΊΠΈΠ½ΠΎΠ², ΠΊΠΎΡΠΎΡΡΠ΅ ΠΏΡΠ΅Π΄ΡΡΠ°Π²Π»ΡΡΡ ΡΠΎΠ±ΠΎΠΉ ΡΠ°Π·Π½ΠΎΠΎΠ±ΡΠ°Π·Π½ΡΡ Π³ΡΡΠΏΠΏΡ Π½Π΅Π±ΠΎΠ»ΡΡΠΈΡ Π±Π΅Π»ΠΊΠΎΠ², ΠΏΡΠΎΠ΄ΡΡΠΈΡΡΠ΅ΠΌΡΡ ΡΠ°Π·Π½ΡΠΌΠΈ ΠΈΠΌΠΌΡΠ½Π½ΡΠΌΠΈ ΠΈ ΡΠΎΡΡΠ΄ΠΈΡΡΡΠΌΠΈ ΠΊΠ»Π΅ΡΠΊΠ°ΠΌΠΈ, ΠΊΠΎΡΠΎΡΡΠ΅, Π΄Π΅ΠΉΡΡΠ²ΡΡ Π² ΠΏΠΈΠΊΠΎΠΌΠΎΠ»ΡΡΠ½ΡΡ ΠΈ Π½Π°Π½ΠΎΠΌΠΎΠ»ΡΡΠ½ΡΡ ΠΊΠΎΠ½ΡΠ΅Π½ΡΡΠ°ΡΠΈΡΡ , Π°ΠΊΡΠΈΠ²ΠΈΡΡΡΡ ΡΠΏΠ΅ΡΠΈΡΠΈΡΠ΅ΡΠΊΠΈΠ΅ ΡΠ΅ΡΠ΅ΠΏΡΠΎΡΡ ΠΈ ΠΌΠΎΠ΄ΡΠ»ΠΈΡΡΡΡ ΡΡΠ½ΠΊΡΠΈΠΈ ΠΌΠ½ΠΎΠ³ΠΈΡ ΠΊΠ»Π΅ΡΠΎΠΊ ΠΈ ΡΠΊΠ°Π½Π΅ΠΉ. Π ΠΎΠ»Ρ ΡΠΈΡΠΎΠΊΠΈΠ½ΠΎΠ² Π² ΠΏΠ°ΡΠΎΠ³Π΅Π½Π΅Π·Π΅ Π²Π°ΡΠΈΠΊΠΎΠ·Π½ΠΎΠΉ Π±ΠΎΠ»Π΅Π·Π½ΠΈ ΠΎΡΡΠ°Π΅ΡΡΡ ΠΌΠ°Π»ΠΎΠΈΠ·ΡΡΠ΅Π½Π½ΠΎΠΉ Π²Π²ΠΈΠ΄Ρ ΡΠ»ΠΎΠΆΠ½ΠΎΡΡΠΈ ΠΈΠ·ΡΡΠ΅Π½ΠΈΡ ΠΈΡ ΠΌΠ΅Ρ Π°Π½ΠΈΠ·ΠΌΠ° Π΄Π΅ΠΉΡΡΠ²ΠΈΡ. ΠΡΠ΅Π΄ΠΏΠΎΠ»Π°Π³Π°Π΅ΡΡΡ, ΡΡΠΎ ΠΈΡ Π°ΠΊΡΠΈΠ²Π½ΠΎΡΡΡ ΠΎΠΏΠΎΡΡΠ΅Π΄ΡΠ΅Ρ Π½Π°ΡΡΡΠ΅Π½ΠΈΡ ΡΠ΅Π³ΡΠ»ΠΈΡΠΎΠ²Π°Π½ΠΈΡ Π΄Π΅Π³ΡΠ°Π΄Π°ΡΠΈΠΈ Π²Π½Π΅ΠΊΠ»Π΅ΡΠΎΡΠ½ΠΎΠ³ΠΎ ΠΌΠ°ΡΡΠΈΠΊΡΠ°, Π²ΠΈΠ΄ΠΎΠΈΠ·ΠΌΠ΅Π½Π΅Π½ΠΈΠ΅ ΡΠΎΡΡΠ°Π²Π»ΡΡΡΠΈΡ Π²Π½Π΅ΠΊΠ»Π΅ΡΠΎΡΠ½ΠΎΠ³ΠΎ ΠΌΠ°ΡΡΠΈΠΊΡΠ°, ΡΠ°ΠΊΠΈΡ ΠΊΠ°ΠΊ ΠΊΠΎΠ»Π»Π°Π³Π΅Π½ ΠΈ ΡΠ»Π°ΡΡΠΈΠ½, ΡΠ½ΠΈΠΆΠ΅Π½ΠΈΠ΅ ΠΊΠΎΠ»ΠΈΡΠ΅ΡΡΠ²Π° Π³Π»Π°Π΄ΠΊΠΎΠΌΡΡΠ΅ΡΠ½ΡΡ ΠΊΠ»Π΅ΡΠΎΠΊ, ΡΡΠΎ ΠΏΡΠΈΠ²ΠΎΠ΄ΠΈΡ ΠΊ ΡΠ½ΠΈΠΆΠ΅Π½ΠΈΡ ΡΡΡΠ΅ΠΊΡΠΈΠ²Π½ΠΎΡΡΠΈ ΡΠΎΠΊΡΠ°ΡΠ΅Π½ΠΈΡ ΡΠΎΡΡΠ΄ΠΈΡΡΠΎΠΉ ΡΡΠ΅Π½ΠΊΠΈ ΠΈΠ·-Π·Π° ΡΡΠ°Π³ΠΌΠ΅Π½ΡΠ°ΡΠΈΠΈ ΠΌΡΡΠ΅ΡΠ½ΠΎΠ³ΠΎ ΡΠ»ΠΎΡ Π²Π΅Π½Ρ. Π¦ΠΈΡΠΎΠΊΠΈΠ½Ρ ΡΡΠ°ΡΡΠ²ΡΡΡ ΠΈ Π² ΠΏΡΠΎΡΠ΅ΡΡΠ°Ρ Π°ΠΊΡΠΈΠ²Π°ΡΠΈΠΈ Π»Π΅ΠΉΠΊΠΎΡΠΈΡΠΎΠ², ΡΡΠΎ ΠΏΡΠΈΠ²ΠΎΠ΄ΠΈΡ ΠΊ Π²ΡΡΠ²ΠΎΠ±ΠΎΠΆΠ΄Π΅Π½ΠΈΡ ΡΠ²ΠΎΠ±ΠΎΠ΄Π½ΡΡ ΡΠ°Π΄ΠΈΠΊΠ°Π»ΠΎΠ², Π°ΠΊΡΠΈΠ²Π°ΡΠΈΠΈ ΠΏΡΠΎΡΠ΅Π°Π·Ρ ΠΈ ΠΏΠΎΡΠ»Π΅Π΄ΡΡΡΠ΅ΠΉ Π΄Π΅Π³ΡΠ°Π΄Π°ΡΠΈΠΈ Π³Π»Π°Π΄ΠΊΠΎΠΌΡΡΠ΅ΡΠ½ΡΡ ΠΊΠ»Π΅ΡΠΎΠΊ. Π ΡΠ°ΠΌΠΊΠ°Ρ Π΄Π°Π½Π½ΠΎΠΉ ΡΠ°Π±ΠΎΡΡ ΠΏΡΠ΅Π΄ΡΡΠ°Π²Π»Π΅Π½Π° ΠΎΠ±ΡΠ°Ρ ΠΈΠ½ΡΠΎΡΠΌΠ°ΡΠΈΡ ΠΎ ΡΠΈΡΠΎΠΊΠΈΠ½Π°Ρ , Π° ΡΠ°ΠΊΠΆΠ΅ ΠΏΡΠΎΠ²Π΅Π΄Π΅Π½ Π°Π½Π°Π»ΠΈΠ· ΠΈΡΡΠ»Π΅Π΄ΠΎΠ²Π°Π½ΠΈΠΉ, Π² ΠΊΠΎΡΠΎΡΡΡ ΠΈΠ·ΡΡΠ΅Π½ΠΎ Π²ΠΎΠ·ΠΌΠΎΠΆΠ½ΠΎΠ΅ Π²Π»ΠΈΡΠ½ΠΈΠ΅ ΡΠ°Π·Π»ΠΈΡΠ½ΡΡ ΠΌΠΎΠ»Π΅ΠΊΡΠ» Π½Π° ΡΠ°Π·Π²ΠΈΡΠΈΠ΅ ΠΏΠ΅ΡΠ²ΠΈΡΠ½ΠΎΠ³ΠΎ Π²Π°ΡΠΈΠΊΠΎΠ·Π½ΠΎΠ³ΠΎ ΡΠ°ΡΡΠΈΡΠ΅Π½ΠΈΡ Π²Π΅Π½.